Semaglutide (Wegovy) tsis tsuas yog ua rau poob phaus tab sis kuj txhim kho lub hauv caug mob rau cov neeg mob hauv caug osteoarthritis (OA) thiab rog,

VIENNA - Cov glucagon-zoo li peptide 1 (GLP-1) receptor agonist semaglutide (Wegovy) tsis tsuas yog ua rau poob phaus tab sis kuj txhim kho lub hauv caug mob rau cov neeg mob hauv caug osteoarthritis (OA) thiab rog, raws li cov txiaj ntsig ntawm KAUJ RUAM 9 Kev tshawb fawb tau tshaj tawm ntawm World Congress ntawm Osteoarthritis (OARSI 2024).

Los ntawm lub hauv paus mus rau lub lim tiam 68, qhov kev hloov pauv ntawm lub hauv caug mob tau soj ntsuam siv Western Ontario thiab McMaster Universities Arthritis Index (WOMAC) qhov mob tau txo qis ntawm 41.7 cov ntsiab lus rau semaglutide thiab txo qis ntawm 27.5 cov ntsiab lus rau qhov sib piv cov placebo. Qhov kwv yees kev kho mob sib txawv ntawm 14.1 cov ntsiab lus ntawm cov pab pawg yog qhov tseem ceeb (P<.001).

Raws li kev poob phaus, qhov no kuj poob los ntawm qhov ntau dua ntawm cov neeg kho nrog semaglutide vs cov neeg muab cov placebo, nrog rau kev txo qis ntawm 13.7% thiab 3.2% los ntawm lub hauv paus, nrog kwv yees li 10.5% qhov hnyav dua nrog semaglutide.

"Qhov tseem ceeb tshaj plaws yog seb puas muaj qhov tshwj xeeb ntawm GLP-1 receptor agonists ntawm kev sib koom ua ke, tsis yog los ntawm kev poob phaus tab sis los ntawm nws tus kheej," tus kws tshawb fawb tus thawj xibfwb Henning Bliddal, MD, DMSc, hais.Medscape Xov Xwm Kho MobUa ntej tshaj tawm cov txiaj ntsig ntawm OARSI 2024.

!https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/ih_240422_henning_bliddal{{ 4 x188.jpg

Henning Bliddal, MD, DMSc

Kev poob phaus yog "zoo meej" vim tias "lub hauv caug raug kev txom nyem los ntawm qhov hnyav. Tab sis txawm tias nws zoo rau lub hauv caug lossis tsuas yog rau kev noj qab haus huv lossis kev noj qab haus huv ntawm tus neeg yog lwm yam teeb meem," said Bliddal, tus thawj coj ntawm Parker. Lub koom haum ntawm Bispebjerg Frederiksberg Tsev Kho Mob hauv Copenhagen, Denmark.

Tsis pom zoo hauv OA

Semaglutide thiab lwm yam tshuaj uas muaj peev xwm poob-inducing tam sim no tsis tau qhia rau kev siv tshwj xeeb hauv OA, Tonia Vincent, MBBS, PhD, hais rauMedscape Xov Xwm Kho Mob, thiab yog li "Kuv xav tias peb yuav tsum tau ceev faj heev," nws hais.

"Kev poob phaus yog ib qho ntawm ob peb yam uas tau pom tias ua tiav hauv kev sim tshuaj," said Vincent, uas yog tus xibfwb ntawm cov leeg nqaij leeg thiab tus kws kho mob rheumatologist ntawm Kennedy Institute of Rheumatology ntawm Oxford University hauv Oxford, England.

"Tib neeg ib txwm zoo siab heev thaum lawv poob phaus, yog li ntawd pab tswj qhov mob. Yog li, kuv xav tsis thoob yog tias tsis muaj txiaj ntsig," nws hais ntxiv.

"Kuv tsuas yog xav tias peb yuav tsum paub ntau ntxiv txog kev siv cov tshuaj no mus ntev, seb lub tsev kho mob puas tuaj yeem them taus lawv, thiab peb yuav faib lawv li cas."

Ua haujlwm dhau los

KAUJ RUAM 9 txoj kev tshawb no tsis yog thawj zaug uas Bliddal tau tshawb xyuas qhov cuam tshuam ntawm GLP-1 receptor agonist hauv cov neeg uas muaj lub hauv caug OA, tab sis nws yog thawj zaug uas tau pom muaj kev cuam tshuam loj rau mob hauv caug.

Yav dhau los, cov txiaj ntsig los ntawm kev sim LOSEIT nrog liraglutide tau pom tias, tom qab 8- lub limtiam kev cuam tshuam kev noj zaub mov hauv lub limtiam, cov neeg uas tau kho nrog GLP-1 receptor agonist poob qhov nruab nrab ntawm 2.8 kg hauv lub cev hnyav. Nyob rau lub sijhawm ntawm 1 xyoos, piv rau 1.2 kg nce hauv pawg placebo. Kev raug mob hauv caug thiab Osteoarthritis Cov qhab nia, txawm li cas los xij, feem ntau tsis cuam tshuam.

Bliddal tau hais tias "Kev tshawb fawb tau ntau dua lossis tsawg dua qhov tsis zoo rau lub hauv caug mob vim tias lub sijhawm ntawd peb yuav tsum tau kho cov neeg mob nrog qee yam kev poob phaus ua ntej lawv raug tso cai kom muaj liraglutide," Bliddal tau hais.

Bliddal tau hais tias "Muaj ntau qhov kev xav sib txawv nrog kev noj zaub mov thiab ntau txoj hauv kev uas [kev hloov pauv kev noj haus] ua, uas tuaj yeem yog ib feem ntawm kev piav qhia vim li cas qee tus neeg tsis pom qhov mob nyem," Bliddal hais.

KAUJ RUAM 9 Kawm Tsim

Tsis muaj kev cuam tshuam kev noj zaub mov ua ntej yuav tsum tau ua hauv STEP 9 sim, txawm hais tias kev noj zaub mov kom tsawg thiab ua kom lub cev muaj zog tau siv nrog rau kev kho semaglutide thiab placebo.

KAUJ RUAM 9 yog ntau lub chaw, ntau lub teb chaws theem 3 kev soj ntsuam kuaj mob uas tau tso npe rau tib neeg yog tias lawv muaj lub cev qhov ntsuas (BMI) ntawm> 30, muaj kev kuaj mob ntawm lub hauv caug OA nrog kev hloov pauv hluav taws xob nruab nrab (Kellgren-Lawrence qib ntawm 2-3 ), thiab tau raug mob hauv caug.

Ntxiv rau qhov qhab nia ntawm WOMAC qhov mob tsawg kawg yog 40 cov ntsiab lus (qhov twg 0 sawv cev tsis muaj thiab 100 qhov mob phem tshaj plaws), cov neeg koom yuav tsum muaj WOMAC cov lej ntsuas ntsuas (NRS) cov qhab nia siab dua lossis sib npaug. 3.1.

Tag nrho ntawm 407 tus neeg koom tau raug xaiv thiab muab faib ua ntu zus, 2: 1, kom tau txais kev txhaj tshuaj subcutaneous ib zaug ib lub lim tiam ntawm semaglutide 2.4 mg lossis placebo rau tag nrho 68 lub lis piam.

Bliddal nthuav tawm cov ntaub ntawv pej xeem tsuas yog rau cov pej xeem kawm tag nrho, qhia tias qhov nruab nrab yog 56 xyoo, 81.6% yog poj niam, 60.9% yog Dawb, 11.8% Neeg Qhab Asmeskas, 7.6% Dub, thiab 19.7% ntawm lwm haiv neeg.

Ntxiv mus, qhov nruab nrab lub cev hnyav ntawm lub hauv paus yog 108.6 kg, thiab qhov nruab nrab lub hauv paus BMI yog 40.3, nrog rau 75% ntawm cov neeg koom muaj BMI ntau dua los yog sib npaug rau 35. Qhov nruab nrab lub duav ncig yog 118.7 cm. Qhov nruab nrab tus qhab nia ntawm WOMAC mob yog 70.9.

Lwm qhov kev tshawb nrhiav

Ntxiv rau qhov kev txo qis pom nyob rau hauv cov ntsiab lus kawg ntawm kev poob phaus thiab mob hauv caug, WOMAC lub cev ua haujlwm tau raug txo los ntawm lub hauv paus mus rau lub lim tiam 68 mus rau qib siab dua hauv semaglutide dua li cov placebo caj npab, los ntawm 41.5 vs 26.7 cov ntsiab lus, nrog. ib qho tseem ceeb kwv yees kev kho mob sib txawv ntawm -14.9 ntsiab lus.

"Kev siv tshuaj kho mob tau poob zoo ib yam; koj tuaj yeem pom qhov poob sai dua hauv pawg semaglutide dua li cov placebo pab pawg, thiab nws tau khaws cia thoob plaws txoj kev tshawb fawb," Bliddal tau hais thaum nws nthuav qhia. Nws tau sau tseg tias cov neeg mob yuav tsum tau tso tseg ib ntus noj cov tshuaj tua kab mob xws li acetaminophen 3 hnub ua ntej lawv qhov mob raug ntsuas.

Cov kev tshawb pom ntxiv tau tshaj tawm hauv qhov paub daws teeb meem, tab sis tsis tau nthuav tawm hauv lub rooj sib tham, yog qhov kev kwv yees qhov sib txawv ntawm qhov kev kho mob tseem ceeb ntawm −1.0 hauv NRS qhov mob hnyav, ntau tus neeg kho nrog semaglutide ntau dua li cov placebo tau txais ntau dua lossis sib npaug li 5% ( 87.

"Kev nyab xeeb thiab kam rau ua nrog semaglutide tau ua raws li lub ntiaj teb STEP program thiab GLP-1 receptor agonist chav kawm feem ntau," Bliddal tau tshaj tawm.

Cov xwm txheej tsis zoo tshwm sim nyob rau hauv ib feem ntawm 10.0% thiab 8.1% ntawm cov neeg koom, thiab cov xwm txheej tsis zoo uas ua rau kev txiav txim siab raug kaw hauv 6.7% thiab 3%. Nyob ib ncig ntawm ib feem peb (2.2%) ntawm cov uas ua rau kev txiav tawm ntawm caj npab semaglutide yog cov xwm txheej tsis zoo hauv plab hnyuv.

STEP 9 txoj kev kawm tau txais nyiaj los ntawm Novo Nordisk. Henning yog tus kws tshawb fawb tseem ceeb rau kev sim thiab lees paub tias cov nyiaj tshawb fawb tau txais los ntawm Novo Nordisk rau nws lub tsev kawm ntawv, nrog rau cov nqi sab laj thiab kev qhuas. Nws kuj tau txais lub rooj sib tham thiab kev txhawb nqa taug kev los ntawm Contura. Vincent tsis tau koom nrog hauv txoj kev tshawb fawb thiab tsis muaj kev cuam tshuam txog kev txaus siab los nthuav tawm.